Regeneron Pharmaceuticals Inc. buy kasimir
Summary
This prediction ended on 02.02.16 with a price of €363.52. The prediction for Regeneron Pharmaceuticals Inc. disappointed with a performance of -12.41%. kasimir has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | -2.870% | -2.870% | 44.387% | 95.074% |
iShares Core DAX® | 1.395% | -0.696% | 15.472% | 15.907% |
iShares Nasdaq 100 | 2.287% | 7.501% | 34.748% | 53.474% |
iShares Nikkei 225® | 1.617% | 2.769% | 11.442% | 8.194% |
iShares S&P 500 | 0.659% | 4.280% | 26.778% | 45.322% |
Comments by kasimir for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Schnäppchenpreis bei Regeneron
Langfristiger Kauf von REGN um die 465$, Ziel 10-20% in 6 Monaten.